For the HR-deficient ovarian cancer, recent studies have shown that the application of the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors rapidly produce synthetic lethality in cells with HR deficiency (HRD) [6–8]. This evidence concerns the gene PARP1 and ovarian carcinoma.